PROOF 301: Infigratinib Versus Gemcitabine Plus Cisplatin for CCA With FGFR2 Rearrangements

Ghassan Abou-Alfa, MD, Memorial Sloan Kettering Cancer Center, discusses the PROOF 301 trial that compared infigratinib against gemcitabine plus cisplatin for patients with cholangiocarcinoma (CCA) with FGFR2 rearrangements.

Dr. Abou-Alfa describes the promising outcomes of infigratinib and delves into further research on FGFR alterations in CCA, along with the importance of presenting trial data from studies that faced early termination.